Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$244.28 USD

244.28
1,118,394

+1.81 (0.75%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Genomic Health (GHDX) Oncotype DX GPS Test Results Positive

Genomic Health's (GHDX) efforts to improve its prostate cancer business are encouraging.

    IDEXX Laboratories Strong on CAG Business Amid Currency Woes

    IDEXX's (IDXX) innovation-based global strategy is leading to growth at CAG Diagnostics.

      Hill-Rom (HRC) Trades on Product Innovation, Competition Rife

      Hill-Rom (HRC) focuses on product innovation, the latest launch being Connex Cardio ECG.

        Integra LifeSciences Global Prospects Solid, Competition Rife

        Integra LifeSciences (IART) witnesses strong global sales within specialty surgical driven by strength in door repair and tissue ablation franchises in Asia Pacific and Europe.

          Edwards Lifesciences (EW) Beats on Q4 Earnings and Revenues

          Edwards Lifesciences (EW) gains from strength in THVT on continued therapy adoption across all geographies in Q4.

            Illumina (ILMN) Tops Q4 Earnings & Revenues, Issues Guidance

            Illumina (ILMN) gains from strength in sequencing consumables and instruments as well as microarray portfolios in Q4.

              Align Technology (ALGN) Q4 Earnings Top on Invisalign Sales

              Align Technology (ALGN) gains on solid contributions from the Clear Aligner as well as Scanner and Service segments in Q4.

                Zimmer Biomet (ZBH) Q4 Earnings Meet Estimates, Sales Beat (Revised)

                Zimmer Biomet (ZBH) rides high on Hip and S.E.T segments in Q4.

                  Abaxis (ABAX) at a 52-Week High: What's Driving the Stock?

                  Abaxis (ABAX) rides high on recently received approval from USDA.

                    ResMed (RMD) Rides on Product Launches, Robust Global Growth

                    ResMed's (RMD) product launches and strategies to gain traction in the sleep-disordered breathing market. This upside is further likely to drive the stock in the future.

                      Intuitive Surgical Gains on FDA Approvals, Competition Rife

                      Intuitive Surgical (ISRG) gains significantly on CE Mark approval for da Vinci X in Europe.

                        Hill-Rom (HRC) Beats Q1 Earnings and Revenues, Margins Up

                        Hill-Rom (HRC) rides on strength in Front Line Care and Surgical Solutions segments in Q1.

                          Abaxis (ABAX) Beats Earnings and Revenue Estimates in Q3

                          Abaxis (ABAX) Q3 earnings gain on strength in Medical and Veterinary segments.

                            Strength Seen in ResMed (RMD): Stock Soars 14.7%

                            ResMed (RMD) was a big mover last session, as the company saw its shares rise more than 14% on the day amid huge volumes.

                              ResMed (RMD) Beats Q2 Earnings & Sales on Growth in All Lines

                              ResMed (RMD) beats earnings and sales in Q2 on solid contributions from domestic and international businesses.

                                Why Earnings Season Could Be Great for ResMed (RMD)

                                ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                                  Can ResMed (RMD) Maintain Balanced Growth in Q2 Earnings?

                                  ResMed (RMD) poised to ride high on continued growth in domestic as well as overseas business in Q2.

                                    ResMed (RMD) Rides on Innovation Amid Reimbursement Woes

                                    ResMed (RMD) achieves strong global revenue growth for the past few quarters on the back of sales of sleep devices, respiratory care devices, mask systems and software solutions.

                                      Why Is ResMed (RMD) Up 8.4% Since the Last Earnings Report?

                                      ResMed (RMD) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                        Can ResMed (RMD) Maintain Balanced Growth in Q1 Earnings?

                                        ResMed (RMD) may ride high in Q1 on continued growth in its domestic as well as overseas business.

                                          Why Is ResMed (RMD) Up 3.1% Since the Last Earnings Report?

                                          ResMed (RMD) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                            ResMed (RMD) Q4 Earnings Top, 2020 Strategic Goals on Track

                                            ResMed's Q4 results (RMD) register strong sales in sleep devices, respiratory care devices, mask systems and software solutions.

                                              Medical Products Earnings Due on Aug 1: IDXX, RMD

                                              There are some powerful long-term tailwinds of the medical device industry which have been a major driving force behind the sector's impressive performance over the past few quarters.

                                                Is a Surprise in Store for ResMed (RMD) in Q4 Earnings?

                                                Currency headwind is likely to dampen ResMed's (RMD) gains in the COPD and sleep apnea market.

                                                  Here's Why You Should Add ResMed to Your Portfolio Now

                                                  California-based ResMed, Inc. (RMD) has been on a healthy growth trajectory of late.